Intellia Therapeutics Inc.

In News

Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout | AI

Kavout | AI - Jul 16, 2026

NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits

Stocktwits - Jul 16, 2026

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics - Jun 13, 2026

Intellia Therapeutics: An Overvalued Biotech With Little To No Commercial Potential (NTLA) - Seeking Alpha

Seeking Alpha - Jul 14, 2026

Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now? - Yahoo Finance

Yahoo Finance - Jul 03, 2026

NTLA Downgraded by Wolfe Research -- Rating Changed to Underperf - GuruFocus

GuruFocus - Jul 16, 2026

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits

Stocktwits - Jul 14, 2026

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - Intellia Therapeutics

Intellia Therapeutics - Apr 27, 2026

Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success - Yahoo Finance

Yahoo Finance - Jul 09, 2026

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics - Apr 27, 2026

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Intellia Therapeutics

Intellia Therapeutics - Feb 26, 2026

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 - Intellia Therapeutics

Intellia Therapeutics - Apr 24, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment